Shots:
- The P-III study involves assessing of SCB-808
(SC) vs Enbrel (SC) in patients with ankylosing spondylitis (radiographic axial
spondyloarthritis) to evaluate its safety, efficacy and PK - The company utilizes its Trimer-Tag technology
platform to develop novel therapies targeting trimerization-dependent pathways
and is also leveraging its cGMP biomanufacturing capabilities to develop biosimilars - SCB-808 is mAb being developed as a prefilled
syringe ready-for-injection self-administered for the treatment of rheumatoid
arthritis and other autoimmune diseases
Click here to read full press release/ article | Ref: GlobeNewswire| Image: Signbox